Literature DB >> 19591229

Introducing transcription factors to multipotent mesenchymal stem cells: making transdifferentiation possible.

Ran Barzilay1, Eldad Melamed, Daniel Offen.   

Abstract

Multipotent mesenchymal stem cells (MSCs) represent a promising autologous source for regenerative medicine. Because MSCs can be isolated from adult tissues, they represent an attractive cell source for autologous transplantation. A straightforward therapeutic strategy in the field of stem cell-based regenerative medicine is the transplantation of functional differentiated cells as cell replacement for the lost or defective cells affected by disease. However, this strategy requires the capacity to regulate stem cell differentiation toward the desired cell fate. This therapeutic approach assumes the capability to direct MSC differentiation toward diverse cell fates, including those outside the mesenchymal lineage, a process termed transdifferentiation. The capacity of MSCs to undergo functional transdifferentiation has been questioned over the years. Nonetheless, recent studies support that genetic manipulation can serve to promote transdifferentiation. Specifically, forced expression of certain transcription factors can lead to reprogramming and alter cell fate. Using such a method, fully differentiated lymphocytes have been reprogrammed to become macrophages and, remarkably, somatic cells have been reprogrammed to become embryonic stem-like cells. In this review, we discuss the past and current research aimed at transdifferentiating MSCs, a process with applications that could revolutionize regenerative medicine.

Mesh:

Substances:

Year:  2009        PMID: 19591229     DOI: 10.1002/stem.172

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  39 in total

Review 1.  Current state of the development of mesenchymal stem cells into clinically applicable Schwann cell transplants.

Authors:  Yu Pan; Sa Cai
Journal:  Mol Cell Biochem       Date:  2012-07-11       Impact factor: 3.396

Review 2.  Bone marrow mesenchymal stem cells: historical overview and concepts.

Authors:  Pierre Charbord
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

Review 3.  Research using Mesenchymal Stem/Stromal Cells: quality metric towards developing a reference material.

Authors:  Vivek Tanavde; Candida Vaz; Mahendra S Rao; Mohan C Vemuri; Radhika R Pochampally
Journal:  Cytotherapy       Date:  2015-09       Impact factor: 5.414

Review 4.  Mesenchymal stem cells: paracrine signaling and differentiation during cutaneous wound repair.

Authors:  Anne M Hocking; Nicole S Gibran
Journal:  Exp Cell Res       Date:  2010-05-13       Impact factor: 3.905

5.  Isolation, characterization, and gene modification of dairy goat mesenchymal stem cells from bone marrow.

Authors:  Yanli Zhang; Yixuan Fan; Ziyu Wang; Yongjie Wan; Zhengrong Zhou; Bushuai Zhong; Lizhong Wang; Feng Wang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2012-07-18       Impact factor: 2.416

6.  Conversion of human bone marrow-derived mesenchymal stem cells into tendon progenitor cells by ectopic expression of scleraxis.

Authors:  Paolo Alberton; Cvetan Popov; Markus Prägert; Julia Kohler; Chisa Shukunami; Matthias Schieker; Denitsa Docheva
Journal:  Stem Cells Dev       Date:  2011-10-11       Impact factor: 3.272

Review 7.  In vitro and in vivo neurogenic potential of mesenchymal stem cells isolated from different sources.

Authors:  Ramyani Taran; Murali Krishna Mamidi; Gurbind Singh; Susmita Dutta; Ishwar S Parhar; John P John; Ramesh Bhonde; Rajarshi Pal; Anjan Kumar Das
Journal:  J Biosci       Date:  2014-03       Impact factor: 1.826

8.  Trans-differentiation of the adipose tissue-derived stem cells into neuron-like cells expressing neurotrophins by selegiline.

Authors:  Alireza Abdanipour; Taki Tiraihi; Alireza Delshad
Journal:  Iran Biomed J       Date:  2011

9.  Mesenchymal stromal cells attenuate multiple sclerosis via IDO-dependent increasing the suppressive proportion of CD5+ IL-10+ B cells.

Authors:  Huijuan Li; Yinan Deng; Jinliang Liang; Feng Huang; Wei Qiu; Min Zhang; Youming Long; Xueqiang Hu; Zhengqi Lu; Wei Liu; Song Guo Zheng
Journal:  Am J Transl Res       Date:  2019-09-15       Impact factor: 4.060

10.  Mesenchymal stromal cells infusions improve refractory chronic graft versus host disease through an increase of CD5+ regulatory B cells producing interleukin 10.

Authors:  Y Peng; X Chen; Q Liu; X Zhang; K Huang; L Liu; H Li; M Zhou; F Huang; Z Fan; J Sun; Q Liu; M Ke; X Li; Q Zhang; A P Xiang
Journal:  Leukemia       Date:  2014-07-18       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.